Bradykinin B(2) receptor blockade and intradialytic hypotension

What Was Tested

Researchers studied Bradykinin in this randomized controlled trial publication.

Who Took Part

The abstract describes 11 patients taking part.

Icatibant or placebo was infused for 30 min before and during hemodialysis in 11 patients on MHD.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Bradykinin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Bradykinin study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Bradykinin, giving a reference point.

In the crossover set-up each of the patients took both Bradykinin and the comparison in turn, acting as their own control.

The researchers performed a post-hoc analysis of a double-blind, placebo-controlled, randomized, 2 × 2 crossover clinical trial comparing the continuous infusion of icatibant, a bradykinin B2 receptor blocker, and placebo during hemodialysis.

What Was Measured

PubMed files the paper under topics including Receptors, Bradykinin, Bradykinin, Hypotension, Renal Dialysis and Blood Pressure.

The authors tagged it with the keywords Hemodialysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bradykinin in 11 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (BMC nephrology), a journal based in England.

More context: the Bradykinin compound page, all human trials.